SCHEMBL20494591

SCHEMBL20494591

OC(c1ccc(Cl)cc1Br)C(F)(F)F

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 1/20 0.35
PDK2 Q15119 4/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
MGLL Q99685 1/20 0.34
S1PR3 Q99500 4/20 0.34
GAA P10253 1/20 0.33
LMNA P02545 1/20 0.32
TP53 P04637 1/20 0.32
HTT P42858 1/20 0.32
TMPRSS4 Q9NRS4 2/20 0.31
S1PR1 P21453 1/20 0.31
PPARA Q07869 1/20 0.31
FLT1 P17948 1/20 0.30
FLT4 P35916 1/20 0.30
KDR P35968 1/20 0.30
BRD4 O60885 1/20 0.30
BRD2 P25440 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL610499 1.00 PDE2A (0.35) PDE2APDK2L3MBTL1MGLLS1PR3
SCHEMBL30027153 1.00 PDE2A (0.35) PDE2APDK2L3MBTL1MGLLS1PR3
SCHEMBL14321311 0.81 TP53 (0.47) PDE2APDK2LMNATP53HTT
SCHEMBL1343758 0.79 APLNR (0.36) PDE2A
SCHEMBL14321599 0.79 TSHR (0.41) PDE2APDK2MGLLGAALMNA
SCHEMBL22852524 0.78 ALDH1A1 (0.44) PDE2APDK2MGLLGAALMNA
SCHEMBL22836962 0.78 ALDH1A1 (0.44) PDE2APDK2MGLLGAALMNA
SCHEMBL18057575 0.78 MGLL (0.48) PDE2APDK2MGLLGAALMNA
SCHEMBL18043683 0.78 GAA (0.37) PDE2APDK2MGLLGAALMNA
SCHEMBL613152 0.78 GAA (0.37) PDE2APDK2MGLLGAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111315746-B Tryptophan hydroxylase inhibitors and pharmaceutical compositions comprising the same 光州科学技术院 2022-11-29 CN disclosed
US-11407763-B2 Tryptophan hydroxylase inhibitor and pharmaceutical composition including same GWANGJU INSTITUTE OF SCIENCE AND TECHNOLGY (KR) 2022-08-09 US disclosed
EP-3674303-B1 NOVEL TRYPTOPHAN HYDROXYLASE INHIBITOR AND PHARMACEUTICAL COMPOSITION INCLUDING SAME GWANGJU INST SCIENCE & TECH (KR) 2022-07-20 EP disclosed
US-20210155634-A1 NOVEL TRYPTOPHAN HYDROXYLASE INHIBITOR AND PHARMACEUTICAL COMPOSITION INCLUDING SAME KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2021-05-27 US disclosed
EP-3674303-A1 NOVEL TRYPTOPHAN HYDROXYLASE INHIBITOR AND PHARMACEUTICAL COMPOSITION INCLUDING SAME Gwangju Institute of Science and Technology (KR) 2020-07-01 EP disclosed
CN-111315746-A Novel tryptophan hydroxylase inhibitors and pharmaceutical compositions comprising the same 光州科学技术院 2020-06-19 CN disclosed
US-10350208-B2 Spirocyclic compounds as tryptophan hydroxylase inhibitors ROIVANT SCIENCES GMBH (CH) 2019-07-16 US disclosed
US-20180256574-A1 SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS ALTAVANT SCIENCES GMBH (CH) 2018-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10350208-B2 Spirocyclic compounds as tryptophan hydroxylase inhibitors TPH1, TPH2, HTR1A PDE2A 3073/4885PDK2 802/4885L3MBTL1 1960/4885
US-20180256574-A1 SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS TPH1, TPH2, HTR1A PDE2A 3073/4885PDK2 802/4885L3MBTL1 1960/4885
US-11407763-B2 Tryptophan hydroxylase inhibitor and pharmaceutical composition including same TPH1, TPH2, IDO1 PDE2A 1690/4885PDK2 715/4885L3MBTL1 4374/4885
US-20210155634-A1 NOVEL TRYPTOPHAN HYDROXYLASE INHIBITOR AND PHARMACEUTICAL COMPOSITION INCLUDING SAME TPH1, TPH2, IDO1 PDE2A 1515/4885PDK2 767/4885L3MBTL1 4359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.